Caroline Wilson

发表

Bone Biomarkers in Research and Clinical Practice

Janet E Brown, L. Zeng, Caroline Wilson, 2014 .

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

D. Cameron, D. Dodwell, R. Bell, 2014, The Lancet. Oncology.

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

M. Ocké, C. V. van Rossum, Caroline Wilson, 2018, EFSA Supporting Publications.

Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study

S. Cross, I. Holen, R. Coleman, 2013, Clinical Cancer Research.

Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women

Caroline Wilson, Diane V Lefley, P. Ottewell, 2021, Frontiers in Endocrinology.

The endocrine influence on the bone microenvironment in early breast cancer.

I. Holen, Caroline Wilson, H. Brown, 2016, Endocrine-related cancer.

Reproductive hormones in breast cancer bone metastasis: The role of inhibins

Caroline Wilson, 2016, Journal of bone oncology.

Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study

D. Cameron, D. Dodwell, R. Bell, 2016, Journal of bone oncology.

The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

I. Holen, R. Coleman, Caroline Wilson, 2015, BMC Cancer.

Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?

Caroline Wilson, P. Ottewell, 2019, Breast cancer : basic and clinical research.

Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance

G. Dore, A. Howe, J. George, 2020, Hepatology communications.

Expression of a human variant of CHMP2B linked to neurodegeneration in Drosophila external sensory organs leads to cell fate transformations associated with increased Notch activity

J. Kavaler, Caroline Wilson, S. T. Ahmad, 2020, Developmental neurobiology.

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover

D. Adamson, R. Coleman, Caroline Wilson, 2016, Journal of bone oncology.

Pharmacotherapy of gestational trophoblastic neoplasia

Caroline Wilson, B. Hancock, Mohammad Khan, 2013 .

Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions

Caroline Wilson, P. Ottewell, M. Muthana, 2020, Journal of bone oncology.

Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer

Janet E Brown, S. Danson, Ameera B A Jailani, 2022, Future Pharmacology.

Abstract S6-4: Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study.

W. Gregory, D. Cameron, R. Bell, 2012 .

A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response

R. Evans, G. Barish, M. Downes, 2013, Cell.

CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials

I. Holen, Caroline Wilson, Lubaid Saleh, 2020, Acta oncologica.

Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.

S. Danson, Caroline Wilson, 2010, Lung Cancer.

Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD

F. Schwartz, E. List, D. Berryman, 2018, The Journal of endocrinology.

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer

I. Holen, Caroline Wilson, Lubaid Saleh, 2021, MedComm.

Toxicity of Bone-Targeted Agents in Malignancy

R. Coleman, Caroline Wilson, Fiona G. Taylor, 2013 .

Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study

Thomas R. Pigott, Yatri R. Shah, M. Theodoulou, 2021, Breast.

Metformin-Mediated Bambi Expression in Hepatic Stellate Cells Induces Prosurvival Wnt/β-Catenin Signaling

R. Evans, M. Downes, C. Liddle, 2012, Cancer Prevention Research.

Bone-targeted agents in the treatment of lung cancer

P. Woll, Caroline Wilson, Shobha Silva, 2015, Therapeutic advances in medical oncology.

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo

Simak Ali, I. Holen, S. Wood, 2023, Cancers.

Abstract P2-02-04: The interaction between menopausal status and zoledronic acid can differentially affect serum levels of the TGFβ superfamily.

I. Holen, R. Coleman, Caroline Wilson, 2012 .

Efficacy of eribulin in breast cancer: a short report on the emerging new data

Caroline Wilson, R. Young, G. Eslamian, 2017, OncoTargets and therapy.

Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer.

R. Coleman, Caroline Wilson, 2016, JAMA oncology.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The metastatic microenvironment of breast cancer: clinical implications.

C. Wilson, I. Holen, W. Gregory, 2013, Breast.

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

D. Cameron, D. Dodwell, R. Bell, 2014, The Lancet. Oncology.